PACERONE

Pacerone Adverse Events Reported to the FDA Over Time

How are Pacerone adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Pacerone, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Pacerone is flagged as the suspect drug causing the adverse event.

Most Common Pacerone Adverse Events Reported to the FDA

What are the most common Pacerone adverse events reported to the FDA?

Drug Interaction	593 (2.22%)
Dyspnoea	498 (1.86%)
Atrial Fibrillation	455 (1.7%)
Ventricular Tachycardia	317 (1.19%)
Dizziness	292 (1.09%)
Hyperthyroidism	287 (1.07%)
Fatigue	278 (1.04%)
Asthenia	273 (1.02%)
Bradycardia	260 (.97%)
Torsade De Pointes	248 (.93%)
Interstitial Lung Disease	240 (.9%)
	Show More
Hypotension	237 (.89%)
Electrocardiogram Qt Prolonged	235 (.88%)
Hypothyroidism	227 (.85%)
Pulmonary Fibrosis	223 (.83%)
Nausea	221 (.83%)
Cardiac Arrest	220 (.82%)
Pneumonia	218 (.82%)
International Normalised Ratio Incr...	210 (.79%)
Pulmonary Toxicity	196 (.73%)
Renal Failure Acute	196 (.73%)
Syncope	186 (.7%)
Condition Aggravated	184 (.69%)
Drug Ineffective	183 (.69%)
Pleural Effusion	170 (.64%)
Cardiac Failure	164 (.61%)
Renal Failure	159 (.6%)
Drug Toxicity	157 (.59%)
Oedema Peripheral	155 (.58%)
Lung Disorder	153 (.57%)
Rhabdomyolysis	149 (.56%)
Alanine Aminotransferase Increased	147 (.55%)
Respiratory Failure	143 (.54%)
Fall	139 (.52%)
Paraesthesia	138 (.52%)
Vomiting	138 (.52%)
Cardiac Failure Congestive	133 (.5%)
Aspartate Aminotransferase Increase...	131 (.49%)
Feeling Abnormal	131 (.49%)
Ventricular Fibrillation	128 (.48%)
Weight Decreased	128 (.48%)
Tremor	127 (.48%)
Arrhythmia	118 (.44%)
Liver Function Test Abnormal	118 (.44%)
Hypokalaemia	115 (.43%)
Cough	110 (.41%)
Cardiac Murmur	109 (.41%)
Blood Creatinine Increased	105 (.39%)
Malaise	103 (.39%)
Pneumonitis	103 (.39%)
Anaemia	102 (.38%)
Oedema	96 (.36%)
Diarrhoea	95 (.36%)
Cardiogenic Shock	89 (.33%)
Loss Of Consciousness	89 (.33%)
Renal Impairment	89 (.33%)
Venous Pressure Jugular Increased	89 (.33%)
Dyspnoea Exertional	88 (.33%)
Multi-organ Failure	88 (.33%)
Acute Respiratory Distress Syndrome	87 (.33%)
Dehydration	87 (.33%)
Pyrexia	87 (.33%)
Pulmonary Oedema	86 (.32%)
Confusional State	85 (.32%)
Hepatotoxicity	81 (.3%)
General Physical Health Deteriorati...	80 (.3%)
Heart Rate Decreased	80 (.3%)
Pain	80 (.3%)
Haemoglobin Decreased	78 (.29%)
Left Ventricular Dysfunction	77 (.29%)
Muscular Weakness	77 (.29%)
Hyponatraemia	76 (.28%)
Chest Pain	75 (.28%)
Hyperhidrosis	75 (.28%)
Blood Creatine Phosphokinase Increa...	73 (.27%)
Liver Disorder	73 (.27%)
Gait Disturbance	72 (.27%)
Hepatic Failure	72 (.27%)
Blood Pressure Decreased	67 (.25%)
Hepatic Enzyme Increased	67 (.25%)
Hypoxia	67 (.25%)
Headache	66 (.25%)
Heart Rate Increased	66 (.25%)
Hyperkalaemia	65 (.24%)
Tachycardia	65 (.24%)
Blood Alkaline Phosphatase Increase...	64 (.24%)
Constipation	64 (.24%)
Skin Discolouration	64 (.24%)
Pericardial Effusion	62 (.23%)
Ventricular Extrasystoles	61 (.23%)
Thyroid Disorder	60 (.22%)
Vision Blurred	60 (.22%)
Death	59 (.22%)
Lung Infiltration	59 (.22%)
Myositis	59 (.22%)
Cardio-respiratory Arrest	58 (.22%)
Decreased Appetite	58 (.22%)
Dissociation	58 (.22%)
Palpitations	58 (.22%)
Sinus Bradycardia	58 (.22%)
Myocardial Infarction	57 (.21%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Pacerone, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Pacerone is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Pacerone

What are the most common Pacerone adverse events reported to the FDA?

Cardiac Arrhythmias	2499 (9.35%)
Respiratory	1430 (5.35%)
Neurological	1347 (5.04%)
Lower Respiratory Tract Disorders	1256 (4.7%)
Cardiac And Vascular Investigations	1018 (3.81%)
Therapeutic And Nontherapeutic Effe...	930 (3.48%)
Hepatic And Hepatobiliary	732 (2.74%)
Thyroid Gland	650 (2.43%)
Hepatobiliary	608 (2.28%)
Epidermal And Dermal Conditions	589 (2.2%)
Infections - Pathogen Unspecified	587 (2.2%)
	Show More
Gastrointestinal Signs	573 (2.15%)
Hematology Investigations	567 (2.12%)
Renal Disorders	556 (2.08%)
Muscle	472 (1.77%)
Heart Failures	467 (1.75%)
Electrolyte And Fluid Balance Condi...	383 (1.43%)
Decreased And Nonspecific Blood Pre...	365 (1.37%)
Injuries	281 (1.05%)
Myocardial	275 (1.03%)
Movement Disorders	266 (1%)
Vision	263 (.98%)
Medication Errors	250 (.94%)
Chemical Injury And Poisoning	226 (.85%)
Renal And Urinary Tract Investigati...	215 (.8%)
Physical Examination Topics	213 (.8%)
Pleural	208 (.78%)
Enzyme	189 (.71%)
Musculoskeletal And Connective Tiss...	188 (.7%)
Gastrointestinal Motility And Defec...	175 (.66%)
Anemias Nonhemolytic And Marrow Dep...	155 (.58%)
Skin Appendage Conditions	152 (.57%)
Coronary Artery	151 (.57%)
Cardiac Disorder Signs	146 (.55%)
Administration Site Reactions	144 (.54%)
Appetite And General Nutritional	144 (.54%)
Bacterial Infectious	143 (.54%)
Metabolic, Nutritional And Blood Ga...	131 (.49%)
Deliria	128 (.48%)
Gastrointestinal Hemorrhages	128 (.48%)
White Blood Cell	128 (.48%)
Procedural And Device Related Injur...	125 (.47%)
Water, Electrolyte And Mineral	125 (.47%)
Central Nervous System Vascular	116 (.43%)
Anxiety Disorders	108 (.4%)
Anterior Eye Structural Change, Dep...	103 (.39%)
Toxicology And Therapeutic Drug Mon...	101 (.38%)
Vascular	99 (.37%)
Peripheral Neuropathies	97 (.36%)
Urinary Tract Signs	96 (.36%)
Endocrine Investigations	94 (.35%)
Body Temperature Conditions	92 (.34%)
Pericardial	91 (.34%)
Bronchial Disorders	88 (.33%)
Fatal Outcomes	84 (.31%)
Mental Impairment	83 (.31%)
Cardiac Valve	78 (.29%)
Ocular Structural Change, Deposit A...	78 (.29%)
Platelet	78 (.29%)
Bone And Joint Injuries	76 (.28%)
Glucose Metabolism Disorders	74 (.28%)
Allergic Conditions	73 (.27%)
Pulmonary Vascular	73 (.27%)
Disturbances In Thinking	71 (.27%)
Skin Vascular Abnormalities	71 (.27%)
Lifestyle Issues	69 (.26%)
Suicidal And Self-injurious Behavio...	69 (.26%)
Embolism And Thrombosis	68 (.25%)
Protein And Chemistry Analyses	68 (.25%)
Headaches	67 (.25%)
Hematological And Lymphoid Tissue T...	66 (.25%)
Depressed Mood Disorders	65 (.24%)
Joint	65 (.24%)
Sleep Disorders	64 (.24%)
Dissociative	58 (.22%)
Gastrointestinal Inflammatory Condi...	58 (.22%)
Peritoneal And Retroperitoneal Cond...	57 (.21%)
Eye	56 (.21%)
Respiratory And Pulmonary Investiga...	54 (.2%)
Vascular Inflammations	54 (.2%)
Neuromuscular	53 (.2%)
Vascular Hypertensive	53 (.2%)
Bone, Calcium, Magnesium And Phosph...	51 (.19%)
Upper Respiratory Tract Disorders	49 (.18%)
Gastrointestinal Ulceration And Per...	46 (.17%)
Cardiac Therapeutic Procedures	45 (.17%)
Coagulopathies And Bleeding Diathes...	45 (.17%)
Seizures	45 (.17%)
Tissue	43 (.16%)
Fungal Infectious	42 (.16%)
Encephalopathies	41 (.15%)
Psychiatric	41 (.15%)
Spleen, Lymphatic And Reticulendoth...	41 (.15%)
Hematological	40 (.15%)
Arteriosclerosis, Stenosis, Vascula...	39 (.15%)
Investigations, Imaging And Histopa...	39 (.15%)
Vascular Hemorrhagic	39 (.15%)
Gallbladder	38 (.14%)
Viral Infectious	38 (.14%)
Nephropathies	34 (.13%)
Gastrointestinal Conditions	33 (.12%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Pacerone, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Pacerone is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.